Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression

Treatment Resistant Depression Clinical Trial

— TMS  

Official title:

Assessment of the Neuronavigation System Coupled With Repetitive Transcranial Magnetic Stimulation. A Randomized Double Blind Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01677078
• Other study ID #: 2011-A01272-39
• Status: Completed
• Phase: N/A
• Start date: January 21, 2013
• Est. completion date: March 25, 2017

Study information

• Verified date: August 2018
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) is a non invasive technique which was shown to be effective in the treatment of major depression.

The dorsolateral prefrontal cortex (DLPFC) is the anatomic target in rTMS studies and the standard (manual) '5-cm method' for positioning the coil over DLPFC is the reference. Nevertheless, it has been criticized due to poor targeting accuracies attributed to inter-subject variability.

Such an inaccuracy could have any therapeutic consequences as a decrease in rTMS efficacy.

Preliminary findings suggest that a more reproductible and accurate method, based upon a neuronavigation system could allow for a better efficacy. This finding has to be replicated with sound methodology.

Investigator's objective is to compare efficacy on mood of coil positioning based upon a neuronavigation device versus coil positioning based upon the standard method.

Description:

Background :

Repetitive Transcranial Magnetic Stimulation (rTMS) is a new tool for major depressive disorder.

rTMS is a non invasive technique allowing for a localized stimulation of cerebral tissue cortex. rTMS uses electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field; this can modify activity in specific or general parts of the brain.

Meta-analyses have stated that rTMS appeared to be effective in the treatment of major depression despite any limits concerning sample sizes and methodological concerns.

Studies have shown that this technique potentiates antidepressants treatment in combination therapy.

It has received FDA approval for the management of major depressive disorder. Stimulation parameters are numerous (frequency, intensity, number of pulses) and their effects are increasingly better understood in order to predict a better balance between efficacy and tolerability.

The dorsolateral prefrontal cortex (DLPFC) is the target in repetitive transcranial magnetic stimulation and the standard (manual) '5-cm method' for positioning the transcranial magnetic stimulation coil over DLPFC is the reference. It has been criticized due to poor targeting accuracies attributed to inter-subject variability.

Such an inaccuracy could have consequences as a decrease in rTMS efficacy. Any preliminary findings suggest that a more reproductible and accurate method, based upon a neuronavigation system could allow for a better efficacy. This finding has to be replicated with sound methodology.

Objectives:

To compare efficacy on mood of coil positioning based upon a neuronavigation device versus coil positioning based upon the standard method.

Investigators hypothesized that an accurate localization and stimulation of DLPFC using neuronavigation would be more effective than the less accurate standard method.

A secondary objective is to compare the efficacy on patient's self perception, on psychomotor symptoms and the tolerability of the two methods.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 107
• Est. completion date: March 25, 2017
• Est. primary completion date: March 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients giving their consent;

• Right handed;

• Age > 18 and < 65;

• With a DSM-IV diagnosis of MDD, single episode or recurrent;

• With an antidepressant treatment unchanged in the 3 last weeks;

• With an MADRS score = 21;

• Benzodiazepine treatments have to be avoided;

Exclusion Criteria:

• Major depressive episode with psychotic characteristics;

• A lifetime of the following axis 1 diagnoses: schizophrenia or substance use disorder (alcohol or other substance);

• Stade 5 of Thase and Rush classification ;

• Involuntary hospitalizations;

• Patients under guardianship;

• Outpatients in case of an increased risk of suicide as assessed by a MADRS item 10 > 3;

• Contraindication for MRI or rTMS: a personal history of a seizure disorder, presence of neurologic or neurosurgical disorder, presence of ferromagnetic material (including intraocular) or metallic medical devices (pacemakers);

• Pregnancy.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Treatment-Resistant
• Treatment Resistant Depression

Intervention

Device:
• Neuronavigation system
Neuronavigation
• Standard localisation method
Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')

Locations

Country	Name	City	State
France	Centre Santé Mentale Angevin CESAME	Angers
France	CHU de Brest	Brest
France	Etablissement Public de Santé Mentale	Quimperlé
France	CHGR	Rennes
France	EPSM Morbihan	St Avé

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response	Response defined as at least 50% reduction in the MADRS score.	Day 44
Secondary	Response	Response is defined as at least 50% reduction in the MADRS score.	Day 14
Secondary	Remission	Remission is defined as a MADRS score = 8.	Day 14 Day 44
Secondary	MADRS	Description: It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.	Day 0, day 14 and day 44
Secondary	BDI	It is a multiple-choice self-report inventory and one of the most widely used instruments for measuring the severity of depression.	Day 0 Day 14 Day 14
Secondary	ERD	It is a 14-item questionnaire which psychiatrists use to measure the intensity of motor retardation.	Day 0 Day 14 day 44